Anaplastic gliomas are characterized by variable clinical and genetic features, but there are few studies focusing on the substratification of anaplastic gliomas. To identify a more objective and applicable classification of anaplastic gliomas, we analyzed whole genome mRNA expression profiling of four independent datasets. Univariate Cox regression, linear risk score formula and receiver operating characteristic (ROC) curve were applied to derive a gene signature with best prognostic performance. The corresponding clinical and molecular information were further analyzed for interpretation of the different prognosis and the independence of the signature. Gene ontology (GO), Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA) were performed for functional annotation of the differences. We found a three-gene signature, by applying which, the anaplastic gliomas could be divided into low risk and high risk groups. The two groups showed a high concordance with grade II and grade IV gliomas, respectively. The high risk group was more aggressive and complex. The three-gene signature showed diagnostic and prognostic value in anaplastic gliomas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742201PMC
http://dx.doi.org/10.18632/oncotarget.5421DOI Listing

Publication Analysis

Top Keywords

anaplastic gliomas
24
high risk
12
diagnostic prognostic
8
mrna expression
8
expression profiling
8
gene set
8
three-gene signature
8
gliomas
7
anaplastic
6
risk
5

Similar Publications

Background: This study is a phase II clinical trial to evaluate the efficacy, safety, and tolerability of the blood-brain barrier (BBB) permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma (HGG) (NCT01967810).

Methods: Seventy-three patients were enrolled in 3 separate arms-recurrent glioblastoma (GBM) (Arm 1), bevacizumab refractory GBM (Arm 2), and grade 3 anaplastic gliomas (AGs) (Arm 3). The study was started in October 2013, and the data were locked on September 29, 2017.

View Article and Find Full Text PDF

Background: Combination therapy with BRAF and MEK inhibitor holds promise for treating gliomas harboring the V600E mutation; however, the development of acquired resistance remains a challenge.

Case Description: We describe a case of repeated recurrent mutant pleomorphic xanthoastrocytoma (central nervous system World Health Organization grade 3) treated with combination therapy with BRAF and MEK inhibitor. The patient received dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor); however, she developed resistance to the combination therapy.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the relationship between motor deficits (MD) in patients after glioma surgery and the proximity of the tumor to key motor pathways, specifically the corticospinal tract (CST).
  • It compares two imaging techniques—conventional Diffusion Tensor Imaging Fiber Tracking (DTI-FT) and q-ball Imaging Fiber Tracking (QBI-FT)—to determine which better predicts postoperative motor impairment.
  • Preliminary results indicate that patients with more severe MD have lesions significantly closer to the CST when analyzed using QBI-FT, suggesting this method could improve neurosurgical planning, although more extensive research is needed to validate these findings.
View Article and Find Full Text PDF

Purpose: Lower-grade gliomas typically exhibit 5-aminolevulinic acid (5-ALA)-induced fluorescence in only 20-30% of cases, a rate that can be increased by doubling the administered dose of 5-ALA. Fluorescence can depict anaplastic foci, which can be precisely sampled to avoid undergrading. We aimed to analyze whether a deep learning model could predict intraoperative fluorescence based on preoperative magnetic resonance imaging (MRI).

View Article and Find Full Text PDF

Stereotactic Photodynamic Therapy of Recurrent Malignant Gliomas.

Sovrem Tekhnologii Med

November 2024

MD, PhD, Associate Professor, Head of the Department of Neurosurgery; Military Medical Academy named after S.M. Kirov, 6 Academician Lebedev St., Saint Petersburg, 194044, Russia.

Unlabelled: is to assess the effectiveness and safety of stereotactic photodynamic therapy (sPDT) with 5-aminolevulinic acid (5-ALA) in patients with recurrent malignant supratentorial gliomas in functionally relevant brain areas.

Materials And Methods: In a retrospective single-center study the results of sPDT with 5-ALA in 10 patients (6 of 10 were male), aged 30 to 62 years (median: 51.5 years; 95% CI: 38-59 years) with recurrent malignant brain gliomas after standard therapy who underwent surgery during the period of 2020-2023 were analyzed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!